ejpmr, 2015,2(4), 1099-1109

SJIF Impact Factor 2.026

EUROPEAN JOURNAL OF PHARMACEUTICAL AND MEDICAL RESEARCH

www.ejpmr.com

Research Article

ISSN 3294-3211

EJPMR

SYNTHESIS, CHARACTERIZATION AND BIOLOGICAL EVALUATION OF 3-FLUORO-4-(MORPHOLIN-4-YL)-N-[2-(THIOPHENE-2-YL) ETHYL] ANILINE DERIVATIVES.

Loganathan Velupillai*[1], Prashant P Dixit[2], M. S. Shingare[1], D.V.Mane[1] and Choudhari B R[3].

[1]Department of Chemistry, Dr. Babasaheb Ambedkar Marathwada University, Aurangabad, Maharashtra, India- 431004.

[2]Department of Microbiology, Dr. Babasaheb Ambedkar Marathwada University, Aurangabad, Sub campus, Osmanabad, Maharashtra, India- 413501.

[3]Department of Chemistry, Jaihind College, Dhule, Maharastra, India-424002.

Article Received on 14/06/2015 **Article Revised on 05/07/2015** **Article Accepted on 26/07/2015**

***Correspondence for Author**

Loganathan Velupillai

Department of Chemistry, Dr. Babasaheb Ambedkar Marathwada University, Aurangabad, Maharashtra, India- 431004.

ABSTRACT

A novel series of eight novel 3-fluoro-4-(morpholin-4-yl)-*N*-[2-(thiophen-2-yl)ethyl]aniline derivatives (7 E – 7 L) have been synthesized from commercially available 3,4-Difluoronirobenzene as a starting material. High yield and high purity indicates lack of side reaction and by product. The chemical structures of the synthesized compounds were confirmed by means of ^{1}HNMR and mass spectral data. The synthesized compounds were then examined for their antibacterial and antifungal activities. Some of them were found to possess good activity.

KEYWORDS: Morpholine, Thiophene, Monofluoroaniline, Antibacterial, Antifungal Activity.

INTRODUCTION

Nitrogen and oxygen containing heterocyclic compounds like morpholine[1] and fused ring morphline[2-5] are very important building blocks in medicinal chemistry[6] field. So the morpholine derivatives are extensively very essential in the drug discovery research, which stimulate research activity in the field of the broad spectrum of biological activity[7] study. After the literature survey that many morpholine derivative molecule are shows very good

biological activity in different therapeutic area such as antibacterial[8], antiviral, anticancer, antimicrobial, antidiabetic, anti-Inflammatory, antimalarial, antifungal[9], Antiemetic etc.



Figure 1: Marketed drugs containing a morpholine ring.

It is well known that the introduction of fluorine[10-13] atom into organic molecule causes dramatic changes in its biological profile, mainly due to high electro negativity of fluorine causes increase lipid solubility. The Thiophene[14-18] containing drugs are Tiagabine hydrochloride, Clopidogrel, Duloxetine hydrochloride, Tioconazole, Ticlopidine, Rivaroxaban. Hence, Thiophene was introduced in our moiety considering the better biological activity in vaster range of therapeutic field. In the present study, some new derivatives has been synthesized. Their characterization was done by spectroscopic methods like ^{1}HNMR and mass spectral data. Further, antibacterial and antifungal activities of these derivatives have been studied.

MATERIALS AND METHODS

All the reagents and solvents were used as obtained from the supplier or recrystallized/redistilled as necessary. The moiety 3,4-Difluoronirobenzene [19-24] is commercially available and is also in Sigma Aldrich. This can be also synthesized as per reported literature. Melting points were recorded on open capillary melting point apparatus and are uncorrected. Mass spectra were recorded on 'LCMS-QP2010s' instrument by direct injection method. Nuclear Magnetic Resonance spectra (^{1}HNMR) Were recorded in DMSO-d_6 & $CDCl_3$ on Bruker advance spectrometer at 400MHz using Tetramethylsilane (TMS) as internal standard and the chemical shift (δ) are reported in parts per million. The purity of the

synthesized compounds was checked by Thin Layer Chromatography, Merck pre-coated plates (silica gel 60 F254) were visualized with UV light. Fungus Culture: Candida sp. Gram-positive microorganisms: Staphylococcus aureus, Staphylococcus albus, Streptococcus faecalis, Bacillus sp and Gram-negative microorganisms: Klebsiella pnuemoniae, Escherichia coli, Pseudomonas sp, Proteus sp were used for biological activity.

Antimicrobial Activity

The antimicrobial activity of all synthesized compounds (7 E – 7 L) was examined by standard literature procedure using agar diffusion method by finding the zone of inhibition of the drug sample against the standard drugs. Compounds were taken as test samples along with a standard drug Ciprofloxacin sample. 10 mg of each test compound was dissolved in 1 ml of Dimethylsulphoxide for preparing stock solution of standard drugs. The organisms employed in the in vitro testing of the compounds were gram-positive and gram-negative. Procedure for the preparation of inoculum for all the organisms was same. The inoculum was prepared from a 24-hours old growth of organism on Nutrient agar slant. With the help of sterile nichrome wire loop, the growth of the organism on slant was aseptically transferred to a tube containing sterile distilled water. The contents of the tube were then shaken properly so as to get uniform cell suspension of the organism. Optical density the innoculum was adjusted to 0.6 on the photoelectric colorimeter by using sterile distilled water, before using it as an inoculum.

The medium, 1.5 g of Nutrient agar (Microbiology grade, Hi Media) was dissolved in 100 ml of sterile distilled water. 3 g of Poloxomer 182 was added as a surfactant to the media to prevent the drug precipitation. 20 ml of this stock solution was transferred to each Petri plate. On to each Petri plate containing 20 ml of sterile Nutrient agar 0.1 ml of an authentic culture (corresponding to 5 X 10^{15} CFU/ml.) of test organisms was spread. Four bore wells were bored on each Petri plate and 5-20 µl of the stock solution was added to it. This corresponds to concentration range of 30 µg/ml of the test compound. The tests were carried out in duplicate. Apart from putting the controls of standard drug (Ciprofloxacin), controls with dimethylsulphoxide (positive control) and without dimethylsulphoxide (negative control) were also included in the test. The Petri plates were put in the dark conditions at 37^0C for 24 hours. At the end of incubation period, the results were interpreted by finding the zone of inhibition.

Antifungal Activity

The antifungal activity of all synthesized compounds (7 E – 7 L) screened against Candida sp in dimethylsulfoxide. Fluconazole was employed as standard drug during the test procedures as references. 10 mg of each test compound was dissolved in 1 ml of Dimethylsulphoxide. 3 gm of Saboraud`s dextrose agar (microbiology grade, Hi Media LABORATORY) was dissolved in 100 ml of sterile distilled water. 3 g of Poloxomer 182 was added as a surfactant to the media to prevent the drug precipitation.

On to each Petri plate containing 20 ml of sterile Saboraud`s dextrose agar (microbiology grade, Hi Media LABORATORY) 0.1 ml of an authentic culture (corresponding to 5 X 10^{15} CFU/ml.) of test organisms was spread. Four bore wells were bored on each Petri plate and 5-20 µl of the stock solution was added to it. This corresponds to concentration range of 30 µg/ml of the test compound. The tests were carried out in duplicate. Apart from putting the controls of standard drug (Fuconazole), controls with dimethyl sulphoxide (positive control) and without dimethyl sulphoxide (negative control) were also included in the test. The test tubes were put in the dark conditions at room temperature for 48 hours. At the end of incubation period, the results were interpreted by finding the zone of inhibition.

EXPERIMENTAL



Figure 3: Synthesis of 3-fluoro-4-(morpholin-4-yl)-*N*-[2-(thiophen-2-yl)ethyl]aniline and their derivatives.

Table1: Physical data of synthesized compounds (7 E – 7 L).

S.No	Code	-R	Molecular Formula	M.wt	M.P (°C)	% Yield
1	7 E		$C_{18}H_{21}FN_2O_2S$	348.43	112-115	
2	7 F		$C_{23}H_{23}FN_2O_2S$	410.50	105-108	
3	7 G		$C_{18}H_{18}F_4N_2O_2S$	402.40	96-99	
4	7 H		$C_{21}H_{27}FN_2O_2S$	390.51	116-119	
5	7 I		$C_{18}H_{18}Cl_3FN_2O_2S$	451.77	114-117	
6	7 J		$C_{19}H_{22}BrFN_2O_2S$	441.35	88-91	
7	7 K		$C_{19}H_{22}BrFN_2O_2S$	441.35	97-100	
8	7 L		$C_{22}H_{23}FN_2O_2S_2$	430.55	124-127	

Preparation of 4-(2-fluoro-4-nitrophenyl)morpholine (A): The 3,4-Difluoronirobenzene (15g, 94mmol) was added to the solution of Morpholine (9.85g, 113mmol), potassium carbonate (19.54g, 141mmol) in N,N-Dimethylformamide (90ml) at room temperature. Then the reaction mixture heated to 80°C and maintained for 4h. After completion of reaction, the reaction was cooled to room temperature and slowly poured into cold water (540ml) and the suspension was stirred at room temperature for 2hr. Filtered and washed with water (30ml), after drying yielded the titled product (A) as yellow solid.

Preparation of 3-fluoro-4-(morpholin-4-yl) aniline (B): The methanol (180ml), compound (A) (18g, 79mmole) and 10% palladium on carbon catalyst (1.8g) was added into the

hydrogenation parr shaker reactor, 30 PSI hydrogen gas pressure applied and the mixture was stirred for 5 hr at room temperature. After completion of reaction, the reaction mass filtered through celited bed washed with methanol (40ml). The filtrate was evaporated under vacuum. Yielded the titled product (B) as brown solid.

Preparation of *N*-[3-fluoro-4-(morpholin-4-yl)phenyl]-2-(thiophen-2-yl)acetamide (C): The 2-Thiopheneacetyl Chloride (12.03g, 74mmol) was added to the solution of compound (B) (14g, 71mmol), Triethylamine (10.82g, 106mmol) in Dichloromethane (140ml) at 0°C and the mixture was stirred for 1hour at 0°C. After completion of reaction of reaction, the solution was evaporated in vacuum and the residue was suspended in ethyl acetate (70ml) and washed with 2×35ml 10% sodium bicarbonate solution. The organic layer dried with sodium sulfate and slowly poured into hexane (210ml) at room temperature. Stirred for 2hr at room temperature. Filtered and washed with hexane (20ml), after drying yielded the titled product (C) as white color solid.

Preparation of 3-fluoro-4-(morpholin-4-yl)-*N*-[2-(thiophen-2-yl)ethyl]aniline (D): The compound (C) (18g, 56mmole) in tetrahydrofuran (90ml) was added slowly to the solution of lithium aluminium hydride (2.55g, 67mmol) in tetrahydrofuran (90ml) at 0°C and the mixture was stirred for 16hr at room temperature. After completion of reaction, the reaction was quenched with wet sodium sulfate. The reaction mass filtered through celite bed washed with tetrahydrofuran 40ml. The filtrate was distilled out completely. Yielding the titled product (D) as white color solid.

General method for the synthesis of compounds (7 E – 7 L): The corresponding acid chloride (1.05 mol.Eq) was added to the solution of compound (D) (1 mol.Eq), Triethylamine (1.1 mol.Eq) in Dichloromethane (10 volume) at 0°C and the mixture was stirred for 15minute at 0°C. After completion of reaction of reaction, the solution was evaporated in vacuum and the residue was suspended in ethyl acetate (5ml) and washed with 2×4ml 10% sodium bicarbonate solution. The organic layer dried with sodium sulfate and slowly poured into hexane (15ml) at room temperature. Stirred for 4hr at room temperature. Filtered and washed with hexane (2ml), after drying yielded the titled product (7 E – 7 L) as white color solid.

RESULTS AND DISCUSSION

The results are obtained from various spectral data are results discussed below.

4-(2-fluoro-4-nitrophenyl)morpholine (A): Off-white solid; Yield 87%; M.W: 226.2; Mol. For: $C_{10}H_{11}FN_2O_3$; ^{1}HNMR (400MHz, DMSO-d_6); δ 8.05-8.01 (1H, m), 7.18 (1H, t, J=8.8 Hz), 3.75 (4H, t, J=5.2 Hz), 3.27 (4H, t, J=4.8 Hz).

3-fluoro-4-(morpholin-4-yl) aniline (B): Off-white solid; Yield 98%; M.W: 196.22; Mol. For: $C_{10}H_{13}FN_2O$; LC-MS (m/z): 197.2 (M+1); ^{1}HNMR (400MHz, DMSO-d_6); δ 6.76 (1H, t, J= 9.6 Hz), 6.36-6.29 (2H, m), 5.01 (2H, s), 3.68 (4H, t, J=4.4 Hz), 2.80 (4H, t, J=3.6 Hz).

***N*-[3-fluoro-4-(morpholin-4-yl)phenyl]-2-(thiophen-2-yl)acetamide (C):** Yellow solid; Yield 83%; M.W: 320.38; Mol. For: $C_{16}H_{17}FN_2O_2S$; LC-MS (m/z): 321.1 (M+1); ^{1}HNMR (400MHz, $CDCl_3$); δ 7.70-7.28 (4H, m), 7.07-7.03 (2H, m), 4.03 (4H, s), 3.97 (2H, s), 3.27 (4H, s), 3.10 (1H, s).

3-fluoro-4-(morpholin-4-yl)-*N*-[2-(thiophen-2-yl)ethyl]aniline (D): A white solid; Yield 98%; M.W: 306.39; Mol. For: $C_{16}H_{19}FN_2OS$; LC-MS (m/z): 307.2 (M+1); ^{1}HNMR (400MHz, $CDCl_3$); δ 8.19 (1H, s), 7.26 (1H, s), 7.19-7.16 (1H, m), 6.96-6.84 (2H, m), 6.50-6.46 (1H, m), 4.28 (2H, s), 4.01 (3H, s), 3.58 (2H, s), 3.42 (1H, m), 3.28 (2H, s), 3.16 (2H, t, J=4.0 Hz).

***N*-[3-fluoro-4-(morpholin-4-yl)phenyl]-*N*-[2-(thiophen-2-yl)ethyl]acetamide (7 E):** A white crystalline solid; Yield 92%; M.W: 348.43; Mol. For: $C_{18}H_{21}FN_2O_2S$; LC-MS (m/z): 349.2 (M+1); ^{1}HNMR (400MHz, DMSO-d_6); δ 7.32 (1H, d, J=4.0 Hz), 7.13-6.85 (5H, m), 3.82-3.73 (6H, m), 3.03 (4H, s), 2.95 (2H, t, J=7.6 Hz), 1.74 (3H, s).

***N*-[3-fluoro-4-(morpholin-4-yl)phenyl]-*N*-[2-(thiophen-2-yl)ethyl]benzamide (7 F):** A white crystalline solid; Yield 89%; M.W: 410.50; Mol. For: $C_{23}H_{23}FN_2O_2S$; LC-MS (m/z): 411.3 (M+1); ^{1}HNMR (400MHz, DMSO-d_6); δ 7.35 (1H, d, J=4.8 Hz), 7.25 (5H, s), 6.97-6.80 (6H, m), 3.99 (2H, t, J=7.2 Hz), 3.68 (4H, s), 3.08 (2H, t, J=6.8 Hz), 2.92 (4H, s).

2,2,2-trifluoro-*N*-[3-fluoro-4-(morpholin-4-yl)phenyl]-*N*-[2-(thiophen-2-yl)ethyl]acetamide (7 G): A white crystalline solid; Yield 96%; M.W: 402.40; Mol. For: $C_{18}H_{18}F_4N_2O_2S$; LC-MS (m/z): 403.2 (M+1); ^{1}HNMR (400MHz, DMSO-d_6); δ 7.38-7.36 (1H, m), 7.20-6.89 (5H, m), 3.90 (2H, t, J=7.6 Hz), 3.73 (4H, t, J=4.4 Hz), 3.07-3.04 (6H, m).

***N*-[3-fluoro-4-(morpholin-4-yl)phenyl]-2,2-dimethyl-*N*-[2-(thiophen-2-yl)ethyl] propanamide (7 H):** A white crystalline solid; Yield 96%; M.W: 390.51; Mol. For:

$C_{21}H_{27}FN_2O_2S$; LC-MS (m/z): 391.2 (M+1); ^{1}HNMR (400MHz, DMSO-d_6); δ 7.34 (1H, d, J=4.4 Hz), 7.04-6.84 (5H, m), 3.74-3.67 (6H, m), 3.04-2.97 (6H, m), 0.95 (9H, s).

2,2,2-trichloro-*N*-[3-fluoro-4-(morpholin-4-yl)phenyl]-*N*-[2-(thiophen-2-yl)ethyl]acetamide (7 I): A white crystalline solid; Yield 87%; M.W: 451.77; Mol. For: $C_{18}H_{18}Cl_3FN_2O_2S$; LC-MS (m/z): 452.1 (M+1); ^{1}HNMR (400MHz, DMSO-d_6); δ 7.37-7.36 (1H, m), 7.21-6.89 (5H, m), 3.95 (2H, s), 3.73 (4H, t, J=4.4 Hz), 3.31-3.04 (6H, m).

3-bromo-*N*-[3-fluoro-4-(morpholin-4-yl)phenyl]-*N*-[2-(thiophen-2-yl)ethyl]propanamide (7 J): A white crystalline solid; Yield 83%; M.W: 441.35; Mol. For: $C_{19}H_{22}BrFN_2O_2S$; LC-MS (m/z): 442.1 (M+1); ^{1}HNMR (400MHz, DMSO-d_6); δ 7.32 (1H, t, J=4.4 Hz), 7.09-6.85 (5H, m), 3.81 (2H, t, J=7.6 Hz), 3.73-3.69 (4H, m), 3.56 (2H, t, J=6.4 Hz), 3.03-2.93 (6H, m), 2.58 (2H, t, J=6.4 Hz).

2-bromo-*N*-[3-fluoro-4-(morpholin-4-yl)phenyl]-*N*-[2-(thiophen-2-yl)ethyl]propanamide (7 K): A white crystalline solid; Yield 89%; M.W: 441.35; Mol. For: $C_{19}H_{22}BrFN_2O_2S$; LC-MS (m/z): 442.1 (M+1); ^{1}HNMR (400MHz, DMSO-d_6); δ 7.34 (1H, d, J=5.2 Hz), 7.14-6.87 (5H, m), 4.28-4.26 (1H, m), 3.82-3.74 (6H, m), 3.05-2.95 (6H, m), 1.62 (3H, d, J=6.0 Hz).

***N*-[3-fluoro-4-(morpholin-4-yl)phenyl]-*N*-[2-(thiophen-2-yl)ethyl]thiophene-2-carboxamide (7 L):** A white crystalline solid; Yield 82%; M.W: 416.53; Mol. For: $C_{21}H_{21}FN_2O_2S_2$; LC-MS (m/z): 417.2 (M+1); ^{1}HNMR (400MHz, DMSO-d_6); δ 7.32 (1H, d, J=5.6 Hz), 7.13 (1H, d, J=4.8 Hz), 6.94-6.76 (7H, m), 4.04 (2H, t, J=7.6 Hz), 3.88 (4H, t, J=4.4 Hz), 3.21 (2H, t, J=7.6 Hz), 3.13 (4H, t, J=4.4 Hz).

BIOLOGICAL EVALUATION

Some of the synthesized compounds showed good antimicrobial activity inhibition. Antimicrobial screening results of the tested compounds are shown in Table 2. All the synthesized compounds showed moderate inhibitory activity and some compound showed good antifungal activity inhibition compared to other compound. Antifungal screening results of the tested compounds are shown in Table 2.

Table 2: Antibacterial and Antifungal activity data of compounds (7 E – 7 L).

Compound No.	Inhibition Zone Diameter (mm)

	I	II	III	IV	V	VI	VII	VIII	IX
7 E	15	19	17	19	15	17	14	14	20
7 F	14	22	24	20	21	20	18	27	25
7 G	12	16	18	20	14	13	13	17	18
7 H	14	19	19	15	10	11	15	11	16
7 I	16	18	17	18	18	19	16	17	19
7 J	12	18	19	13	15	15	17	20	21
7 K	17	20	22	18	20	19	19	24	25
7 L	14	17	19	15	13	17	16	20	22
Control (Solvent)	10	12	14	12	13	14	12	11	13
Ciprofloxacin	---	21	22	15	14	16	17	22	23
Fluconazole	15	---	---	---	---	---	---	---	---

Microbial Cultures Used to test antimicrobial Activity, *Fungus Culture:* I-Candida sp. *Gram Positive Bacteria:* II-Staphylococcus aureus, III-Staphylococcus albus, VIII-Streptococcus faecalis, IX- Bacillus sp. *Gram Negative Bacteria :* IV-Klebsiella pnuemoniae, V-Escherichia coli, VI- Pseudomonas sp, VII- Proteus s.

CONCLUSION

In this study, the synthesis of some fused ring benzomorpholine derivatives (7 E – 7 L) was performed and their structures were confirmed by ^{1}HNMR, Mass spectroscopy techniques. In addition, the newly synthesized compounds were screened for their antibacterial and antifungal activities. Some of them were found to possess good antifungal and antibacterial activity.

ACKNOWLEDGMENTS

The authors are thankful to Head of the Department of Chemistry, Dr. Babasaheb Ambedkar Marathwada University, Aurangabad, Maharashtra, India for providing research facilities.

REFERENCES

1. Review of morpholine and its derivatives, Merck Index, 12th ed. published by Merck & co, Whitehouse Station, NJ, 1996; 1074-5.
2. Pushpak Mizar, Bekington Myrboth. Synthesis of substituted 4-(3-alkyl-1,2,4-oxadiazol-5-ylmethyl)-3,4-dihydro-2H-1,4-benzoxazines and 4-(1H-benzimidazol-2-ylmethyl)-3,4-dihydro-2H-1,4-benzoxazines. Tetrahedron Letters. 2006; 47(44): 7823-26.
3. Satoshi Sakami, Koji Kawai, Masayuki Maeda, Takumi Aoki, Hideaki Fujii, Hiroshi Ohno et al. Design and synthesis of a metabolically stable and potent antitussive agent, a novel δ opioid receptor antagonist, TRK-851. Bioorg Med Chem. 2008; 16(17): 7956-67.

4. Gang Zhou, Nicolas Zorn , Pauline Ting , Robert Aslanian , Mingxiang Lin , John Cook et al. Development of Novel Benzomorpholine Class of Diacylglycerol Acyltransferase I Inhibitors. Med Chem Lett. 2014; 5(5): 544-49.
5. Xianhai Huang, Dmitri Pissarnitski, Hongmei Li, Theodros Asberom, Hubert Josien, Xiaohong Zhu et al. Efficient synthesis and reaction pathway studies of novel fused morpholine oxadiazolines for use as gamma secretase modulators. Tetrahedron Letters. 2012; 53(47): 6451-55.
6. Madhu Chopra, VK Ahluwalia. Ane's Student Edition, Text Book of Medicinal Chemistry, 1st ed. New Delhi Published by Ane's Books Pvt. Ltd, 2008.
7. Basudeb Achari, Sukhendu BM, Pradeep Dutta**,** Chinmay Chowdhury. Perspectives on 1, 4-Benzodioxions, 1, 4-Benzoxazines and Their 2, 3- Dihydro Derivatives. Synlett. 2004; 14: 2449-67.
8. Duhalde V, Lahillie B, camou F, Pedeboscq S, pometan JP. Proper use of antibiotics: a prospective study on the use of linezolid in a French university hospital. Pathologie biologie. 2007; 55(10): 478-81.
9. Marireau C; Guilloton M; kartst F. In vivo effects of fenpropimorph on the yeast Saccharomyces cerevisiae and determination of the molecular basis of the antifungal property. Antimicrobial agents and chemotheraphy. 1990; 34(6): 989-93.
10. Diana Gimemez, Cecilia Andreu, Marcel lidel olmo, Tersa varea, Dolores Diaz, Gregorio Asensio. The introduction of fluorine atoms or trifluoromethyl groups in short cationic peptides enhances their antimicrobial activity. Bioor Med Chem. 2006; 14(20): 6971-78.
11. Böhm HJ, Banner D, Bendels S, Kansy M, Kuhn B, Müller K et al. Fluorine in Medicinal Chemistry. Chembiochem. 2004; 5(5): 637-43.
12. John W Clader. The discovery of ezetimibe: a view from outside the receptor. J. Med. Chem. 2004; 47: 1-9.
13. Massa MA, Spangler DP, Durley RC, Hickory BS, Connolly DT, Witherbee BJ et al. Novel heteroaryl replacements of aromatic 3-tetrafluoroethoxy substituents in trifluoro-3-(tertiaryamino)-2-propanols as potent inhibitors of cholesteryl ester transfer protein. Bioor Med Chem Lett, 2001; 11: 1625-28.
14. Synthesis, properties and biological activity of thiophene: A review. Raghav Mishra, K K Jha, Sachin Kumar, Isha Tomer. Der Pharma Chemica. 2011; 3(4): 38-54.
15. A mini review of thiophene derivatives. Ashish Das. International Journal of Institutional Pharmacy and Life Sciences. May-June 2014; 4(3).

16. Thiophene containing triarylmethanes as an titubercular agents. Maloy Kumar Parai, Gautam Panda, Vinita Chaturvedi, Y K Manju, Sudhir Sinha. Bioorganic & medicinal Chemistry Letters. Jan-2008; 18(1): 289-292.
17. Anti-breast cancer activity of some novel 1, 2-dihydropyridine, thiophene and thiazole derivatives. Mansour S Al-Said, Mahmoud S Bashandy, Saleh I Al-qasoumi, Mostafa M Ghorab. E J Med Chem. Jan-2011; 46(1): 137-141.
18. https://en.wikipedia.org/wiki/Thiophene
19. A novel method for the nitration of simple aromatic compounds. Smith Keith, Musson Adam, Gareth A DeBoos. J Org Chem. 1998; 63(23): 8448-8454.
20. Aromatic nitration with potassium nitrate or nitric acid and boron trifluoride monohydrate. Olah George A, Wang Qi, Xing-Ya Li, Bucsi Imre. Synthesis. 1992; 11: 1085-6.
21. Elemental fluorine Part 12. Fluorination of 1,4-disubstituted aromatic compounds. Richard D Chambers, John Hutchinson, Matthew E Sparrowhawk, Graham Sandford, John S Moilliet, Julie Thomson. Journal of Fluorine Chemistry. 2000; 102(1-2): 169-173.
22. Synthesis of aromatic fluoro compounds by nucleophilic exchange of nitro groups by fluoride. Effenberger Franz, Streicher Willi. Chemische Berichte. 1991; 124(1): 157-62.
23. Efficient phosphorus catalysts for the halogen-exchange (Halex) reaction. Lacour Marie-Agnes, Zablocka Maria, Duhayon Carine, Majoral Jean-Pierre, Taillefer Marc. Advanced Synthesis & Catalysis. 2008; 350(17): 2677-2682.
24. Continuous flow coupling and decarboxylation reactions promoted by copper tubing. Zhang Yun, Jamison Timothy F, Patel Sejal, Mainolfi Nello. Organic Letters. 2011; 13(2): 280-283.